Interesting segment today on CNBC about The Epipen
Post# of 405
Bottom line takeaway from the back and forth was - FDA should get moving on more generic drug approvals as they will bring costs DOWN and create more competition. Clearly, they cater to big Pharma but the segment made them look BAD IMO.
http://video.cnbc.com/gallery/?video=3000545665
** Pitts was once one of their own